Coronavirus

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

Staff September 28, 2026

SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Staff September 24, 2026

Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgeryGlobal...

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Staff September 23, 2026

SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the...

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Staff September 16, 2026

Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and...

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Staff September 15, 2026

SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Davos Healthcare™ Launches Global AI-Powered Hospital Evaluations at C3 New York Summit

Staff September 14, 2026

Ambassador Deborah Birx Announces New Data-Driven Framework Evaluating 16,239 Hospitals Across 65 CountriesNEW YORK, Sept. 14, 2026 /PRNewswire/ -- At...

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Staff September 8, 2026

SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Health Canada Approves Sunshine Biopharma’s Atenolol for Treating and Managing Cardiovascular Conditions

Staff August 31, 2026

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

Staff August 31, 2026

SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Staff August 26, 2026

K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma modelsProgram targets a tumor suppressor...

Dr. Vinson Eugene Allen Provided Critical Guidance as Actor Ernest Harden Jr. Faced a Medical Emergency While Filming The Pitt

Staff August 20, 2026

Beloved Actor Ernest Harden Jr. is Grateful, Healthy and Excited to Get Back to Work LOS ANGELES, CA / ACCESS...

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Staff August 19, 2026

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034Enalapril is a widely prescribed ACE inhibitor used to treat...

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Staff August 18, 2026

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Staff August 10, 2026

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Staff August 7, 2026

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengthsLaunch expands Sunshine Biopharma's growing portfolio of essential...

Manufacturing PMI® at 55.6%; July 2026 ISM® Manufacturing PMI® Report

Staff August 3, 2026

New Orders Growing; Production Growing; Employment Growing; Supplier Deliveries Slowing; Raw Materials Inventories Growing; Customers' Inventories Too Low; Prices Increasing;...

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Staff July 28, 2026

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Health Canada Approves Sunshine Biopharma’s Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

Staff July 28, 2026

FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Staff July 24, 2026

SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical...

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Staff July 22, 2026

SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...